Core Viewpoint - WuXi Biologics (02269) has raised its full-year revenue guidance for 2025 from 12%-15% to 14%-16%, indicating strong growth potential in its financial performance [1] Financial Performance - The company reported a 16.1% year-on-year increase in revenue for the first half of the year, reaching RMB 9.95 billion, with a 20.2% growth in continuing operations revenue [1] - EBITDA increased by 50.5% year-on-year to RMB 4.22 billion, while net profit rose by 54.8% to RMB 2.76 billion [1] - Profit attributable to shareholders grew by 56.0% to RMB 2.34 billion, and adjusted net profit increased by 11.6% to RMB 2.84 billion, with an adjusted net profit margin of 28.5% [1] Project and Order Growth - The company signed 86 new comprehensive projects in the first half of the year, setting a historical record for the same period, bringing the total number of comprehensive projects to 864 [1] - The total value of uncompleted orders reached USD 20.34 billion, with an increase of USD 4.21 billion in uncompleted orders over the past three years, indicating a significant growth in revenue expectations [1] Market Environment - The overall innovation drug investment and financing market is recovering, and active licensing transactions are expected to support the continued growth of WuXi Biologics and other leading CXO companies [1]